263 related articles for article (PubMed ID: 25777274)
1. Targeting AMPK Signaling Pathway to Overcome Drug Resistance for Cancer Therapy.
Wang Z; Liu P; Chen Q; Deng S; Liu X; Situ H; Zhong S; Hann S; Lin Y
Curr Drug Targets; 2016; 17(8):853-64. PubMed ID: 25777274
[TBL] [Abstract][Full Text] [Related]
2. AMPK and Cancer.
Wang Z; Wang N; Liu P; Xie X
Exp Suppl; 2016; 107():203-226. PubMed ID: 27812982
[TBL] [Abstract][Full Text] [Related]
3. Targeting AMPK-ULK1-mediated autophagy for combating BET inhibitor resistance in acute myeloid leukemia stem cells.
Jang JE; Eom JI; Jeung HK; Cheong JW; Lee JY; Kim JS; Min YH
Autophagy; 2017 Apr; 13(4):761-762. PubMed ID: 28118076
[TBL] [Abstract][Full Text] [Related]
4. Autophagy facilitates lung adenocarcinoma resistance to cisplatin treatment by activation of AMPK/mTOR signaling pathway.
Wu T; Wang MC; Jing L; Liu ZY; Guo H; Liu Y; Bai YY; Cheng YZ; Nan KJ; Liang X
Drug Des Devel Ther; 2015; 9():6421-31. PubMed ID: 26715839
[TBL] [Abstract][Full Text] [Related]
5. Targeting autophagy to overcome drug resistance in cancer therapy.
Kumar A; Singh UK; Chaudhary A
Future Med Chem; 2015 Aug; 7(12):1535-42. PubMed ID: 26334206
[TBL] [Abstract][Full Text] [Related]
6. Targeting the 5'-AMP-activated protein kinase and related metabolic pathways for the treatment of prostate cancer.
Popovics P; Frigo DE; Schally AV; Rick FG
Expert Opin Ther Targets; 2015 May; 19(5):617-32. PubMed ID: 25600663
[TBL] [Abstract][Full Text] [Related]
7. The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy.
Yuan J; Dong X; Yap J; Hu J
J Hematol Oncol; 2020 Aug; 13(1):113. PubMed ID: 32807225
[TBL] [Abstract][Full Text] [Related]
8. Deciphering the metabolic role of AMPK in cancer multi-drug resistance.
Tan W; Zhong Z; Carney RP; Men Y; Li J; Pan T; Wang Y
Semin Cancer Biol; 2019 Jun; 56():56-71. PubMed ID: 30261277
[TBL] [Abstract][Full Text] [Related]
9. Cryptotanshinone activates AMPK-TSC2 axis leading to inhibition of mTORC1 signaling in cancer cells.
Chen W; Pan Y; Wang S; Liu Y; Chen G; Zhou L; Ni W; Wang A; Lu Y
BMC Cancer; 2017 Jan; 17(1):34. PubMed ID: 28061838
[TBL] [Abstract][Full Text] [Related]
10. The novel inhibitor BRM270 downregulates tumorigenesis by suppression of NF-κB signaling cascade in MDR-induced stem like cancer-initiating cells.
Mongre RK; Sodhi SS; Ghosh M; Kim JH; Kim N; Park YH; Kim SJ; Heo YJ; Sharma N; Jeong DK
Int J Oncol; 2015; 46(6):2573-85. PubMed ID: 25872586
[TBL] [Abstract][Full Text] [Related]
11. Targeting AMPK in the treatment of malignancies.
Vakana E; Altman JK; Platanias LC
J Cell Biochem; 2012 Feb; 113(2):404-9. PubMed ID: 21928327
[TBL] [Abstract][Full Text] [Related]
12. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
Shapira A; Livney YD; Broxterman HJ; Assaraf YG
Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
[TBL] [Abstract][Full Text] [Related]
13. Targeting cancer stem cell-specific markers and/or associated signaling pathways for overcoming cancer drug resistance.
Ranji P; Salmani Kesejini T; Saeedikhoo S; Alizadeh AM
Tumour Biol; 2016 Oct; 37(10):13059-13075. PubMed ID: 27561758
[TBL] [Abstract][Full Text] [Related]
14. Targeting autophagy in cancer stem cells as an anticancer therapy.
Lei Y; Zhang D; Yu J; Dong H; Zhang J; Yang S
Cancer Lett; 2017 May; 393():33-39. PubMed ID: 28216370
[TBL] [Abstract][Full Text] [Related]
15. Reversal of multidrug resistance by gefitinib via RAF1/ERK pathway in pancreatic cancer cell line.
Xiao Z; Ding N; Xiao G; Wang S; Wu Y; Tang L
Anat Rec (Hoboken); 2012 Dec; 295(12):2122-8. PubMed ID: 22907845
[TBL] [Abstract][Full Text] [Related]
16. Role of AMP-activated protein kinase in cancer therapy.
Rehman G; Shehzad A; Khan AL; Hamayun M
Arch Pharm (Weinheim); 2014 Jul; 347(7):457-68. PubMed ID: 24677093
[TBL] [Abstract][Full Text] [Related]
17. Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer.
Du B; Shim JS
Molecules; 2016 Jul; 21(7):. PubMed ID: 27455225
[TBL] [Abstract][Full Text] [Related]
18. Cetylpyridinium chloride is a potent AMP-activated kinase (AMPK) inducer and has therapeutic potential in cancer.
Allen SA; Datta S; Sandoval J; Tomilov A; Sears T; Woolard K; Angelastro JM; Cortopassi GA
Mitochondrion; 2020 Jan; 50():19-24. PubMed ID: 31654752
[TBL] [Abstract][Full Text] [Related]
19. Targeting autophagy augments the activity of DHA-E3 to overcome p-gp mediated multi-drug resistance.
Xi G; Wang M; Sun B; Shaikh AS; Liu Y; Wang W; Lou H; Yuan H
Biomed Pharmacother; 2016 Dec; 84():1610-1616. PubMed ID: 27825801
[TBL] [Abstract][Full Text] [Related]
20. Compound C induces protective autophagy in cancer cells through AMPK inhibition-independent blockade of Akt/mTOR pathway.
Vucicevic L; Misirkic M; Janjetovic K; Vilimanovich U; Sudar E; Isenovic E; Prica M; Harhaji-Trajkovic L; Kravic-Stevovic T; Bumbasirevic V; Trajkovic V
Autophagy; 2011 Jan; 7(1):40-50. PubMed ID: 20980833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
